# Champions Oncology, Inc.: Form 10-Q for the period ended Jan 31, 2015

- Company: [Champions Oncology, Inc.](/companies/csbr.md) (CIK 771856)
- Form: 10-Q
- Filed: 2015-03-17
- Accepted by EDGAR: Mar 17, 2015, 17:25 ET
- Period: 2015-01-31
- Accession: 0001144204-15-016811
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/771856/000114420415016811/v403533_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/771856/000114420415016811/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2015-01-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2014-11-01 to 2015-01-31 | $1.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2014-05-01 to 2015-01-31 | $3.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2014-11-01 to 2015-01-31 | −$3.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2014-05-01 to 2015-01-31 | −$10.8m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2014-11-01 to 2015-01-31 | $12.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2014-05-01 to 2015-01-31 | $27.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2014-11-01 to 2015-01-31 | −$2.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2014-05-01 to 2015-01-31 | −$9.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2014-11-01 to 2015-01-31 | −$0.05 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2014-05-01 to 2015-01-31 | −$0.16 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2014-11-01 to 2015-01-31 | −$0.04 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2014-05-01 to 2015-01-31 | −$0.14 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2014-11-01 to 2015-01-31 | 67,245,577 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2014-05-01 to 2015-01-31 | 67,243,142 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2014-05-01 to 2015-01-31 | −$7.6m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 9 months, 2014-05-01 to 2015-01-31 | $84.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2015-01-31 | $182.0k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2015-01-31 | $1.5m | us-gaap:AssetsCurrent |
| Total assets | at 2015-01-31 | $2.8m | us-gaap:Assets |
| Current liabilities | at 2015-01-31 | $6.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2015-01-31 | $7.0m | us-gaap:Liabilities |
| Shareholders' equity | at 2015-01-31 | −$4.1m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/771856/000114420415016811/v403533_10q.htm

Filed Mar 17, 2015.
Source: SEC EDGAR, the filing index for accession 0001144204-15-016811. Last ingested by Listed: Nov 10, 2026, 03:33 ET. No prices; not investment advice.
